Cardiology Letters 2015, 24(4):230-237
Strategy of combination antihypertensive therapy
- Klinika kardiológie a angiológie, Lekárska fakulta Slovenskej zdravotníckej univerzity, Národný ústav srdcových a cievnych chorôb, a.s., Bratislava, Slovenská republika
High blood pressure (BP) as a symptom as well a as clinical disease is caused by multifactorial processes, e.g. on the basis of various pathophysiological "error" events in maintaining the physiological blood flow regulation. Treatment of hypertension may therefore be effective and long-term efficient only if it affects synchronously the many disturbed regulatory areas which maintain the normal function of the cardiovascular (CV) system (heart, central and peripheral arteries) and various other organs (especially kidneys and central nervous system). The vast majority of hypertensive patients require a combination of at least two antihypertensive agents to reach the target blood pressure. Based on knowledge of the hypertension pathophysiology it is possible to stress 3 basic practical clinical conclusions: (1) It is necessary to diagnose hypertension correctly as soon as possible, stratify, and then start the treatment, while (2) in the hypertension treatment it is a pathophysiologically correct to intervene simultaneously in several potential aetiological positions responsible for the rise and maintenance of elevated BP, (3) this treatment should be at the same time act as preventive protection for systems and organs that are most vulnerable to the effects of high BP. The complex and combined pharmacological antihypertensive treatment is therefore lege artis procedure, on the basis of evidence-based medicine (EBM). The aim of this overview is the drug antihypertensive therapy and the decision making process for monotherapy and combination therapy. It describes the principles of correct choice of drug therapy when combining two or more antihypertensive drugs based on EBM. The article specifically covers various aspects of fixed dual combinations and fixed triple combinations in clinical practice. Since hypertension is the largest risk factor for the current overall mortality and CV mortality in the adult population, it is necessary to understand it scientifically at all levels and clinically and to support this in community and health programmes.
Keywords: arterial hypertension; antihypertensive treatment goals; choice of combination therapy; free combinations; fixed dual combinations; fixed triple combinations
Published: April 1, 2015 Show citation
References
- Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, La urent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
Go to original source... - Filipová S, Dukát A, Škultétyová D. Aký je prínos nových odporúčaní pre diagnostiku a liečbu hypertenzie? Komentár k 2013 ESH/ESC Odporúčaniam pre manažment artériovej hypertenzie. Cardiology Lett 2014;23(1):5-9.
- NICE 2011. Guidelines on hypertension: clinical management of primary hypertension in adults. August 2011. http://publications.nice.org.uk/hypertension-cg127.
- Filipová S, Dukát A, Foltán V, Gajdošík J, Jonáš P. Štandardný diagnostický a terapeutický postup. Odborné odporúčania pre klinickú prax. 59. Metodický list racionálnej farmakoterapie. Artériová hypertenzia. Vyd. Herba, ročník 17, 1-3/2014:1-16.
- Ezzati M, Lopez AD, Rodgers A, Vander Hoer S, Murray CJL. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360.
Go to original source... - Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010;24:336-344.
Go to original source... - Gradman AH. Drug combinations. In: Izzo Jr JL, Sica DA, Black HR. (Eds). Hypertension Primer. The Essentials of high blood pressure. 4th Edition. Philadelphia: Lippincott Williams and Wilkins; 2008:435-439.
- Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-BP Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895906.
Go to original source... - ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular outcomes in patients with type 2 diabetes mellitus: results of the blood pressure lowering arm of the ADVANCE trial. Lancet 2007;370:829840.
Go to original source... - PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regiment among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
Go to original source... - ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008;358:1547-1559.
Go to original source... - Odborné usmernenie Ministerstva zdravotníctva Slovenskej republiky na poskytovanie ambulantnej zdravotnej starostlivosti dospelým pacientom s artériovou hypertenziou. Normatívna časť 33. In: Vestník MZ SR 2014; 62(29.decembra 2014), čiastka 45-60:258-293.
- Falaschetti E, Mindell J, Knott C, Poulter N. Major improvements in hypertension management in England. Serial cross sectional data from 1994 to 2011. Lancet 2014;383(9932):1912-1919.
Go to original source... - Pšenková M, Mackovičová S, Marčišová M, Ondrušová M. Vplyv regulácií na spotrebu antihypertenzív na Slovensku. Cardiology Lett 2015;24(1):5-18.
- Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011;34(1):87-90.
Go to original source... - Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29(3):610618.
Go to original source... - Herttua K, Tabák AG, Martikainen P, Vahtera J, Kivimäki M. Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study. Eur Heart J 2013;34:2933-2939.
Go to original source... - Poulter N. Triple therapy and beyond. In: Multiple combination therapy in hypertension. Abdon (UK): Nova Professional Media Ltd.; 2014:71-75.
- Castellano JE, Sanz G, Fuster V. Evolution of the polypill concept and ongoing clinical trials. Can J Cardiol 2014;30:520-526.
Go to original source... - Bournier M. Antihypertensive combination treatment: State of the art. Curr Hypertens Rep 2015;17:51.
Go to original source...

